The efficacy of <i>Cordyceps sinensis</i> preparations in improving kidney outcomes among patients with AKI during hemorrhagic fever with renal syndrome: evidence from a Chinese cohort

Overall, 27.3% of patients with HFRS-AKI progressed to CKD despite receiving supportive care. Facial flushing was more frequent in the ICR group than in the CR group (40.7% vs. 18.1%, <i>p</i> = 0.033). Multivariate analysis revealed that treatment with <i>Cordyceps sinensis</i> preparations during the AKI phase was an independent protective factor against incomplete kidney recovery (OR: 0.323, 95% CI: 0.114–0.916, <i>p</i> = 0.034).

Inverse probability weighting analysis further demonstrated that the use of <i>Cordyceps sinensis</i> preparations was inversely associated with incomplete kidney recovery (β: −1.184, 95% CI: −2.224 – −0.144, <i>p</i> = 0.026). Survival analysis confirmed that <i>Cordyceps sinensis</i> preparation therapy was associated with improved kidney outcomes (log-rank test, <i>p</i> = 0.004). This study provides the first clinical evidence that adjunctive therapy with <i>Cordyceps sinensis</i> preparations during HFRS-AKI is associated with improved kidney outcomes, suggesting that <i>Cordyceps sinensis</i> preparations represents a promising therapeutic approach for viral-induced AKI.</p>